Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
Take Tell Us What YOU Think! Take The Body's Visitor Survey!
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

FDA Grants Tentative Approval for Aurobindo's Antiretroviral Drug Abacavir

From Henry J. Kaiser Family Foundation

May 25, 2006

Indian drug manufacturer Aurobindo Pharma has received tentative approval from FDA to produce 300 mg tablets of abacavir sulfate, which is used in combination with other antiretroviral drugs to treat HIV-1 infection, the company announced on Tuesday, the Hindu Business Line reports. Abacavir is the generic version of GlaxoSmithKline's Ziagen. The product will be eligible for consideration under the President's Emergency Plan for AIDS Relief, according to a press release from the company (Hindu Business Line, 5/24).

Back to other news for May 25, 2006


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2006 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report.
 
See Also
More HIV News

 

Advertisement